Herpes simplex
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
Herpes simplex i runga i te ngutu.
Herpes simplex ― Ko te mate Herpes simplex i roto i nga maihao he nui ake i nga tamariki nohinohi atu i nga pakeke.
relevance score : -100.0%
ReferencesKo te mate HSV‑1 ka ahu whakamua i roto i te mate tuatahi o ngā pūtau epithelial, ka whai i te torohūtanga, te nuinga i roto i ngā neurons, me te whakaohooho. Ko HSV‑1 te nuinga o te wā ka puta te hūnga vesicular tuatahi me te auau, te nuinga ki te waha me te mucosa taihemahema. Ko ōna whakaaturanga mai i te herpes orolabial ki ngā momo ahuatanga pērā i te herpetic folliculitis, herpetic sycosis, herpes ocular, me te herpes encephalitis. Ka awhina te rongoā antiviral ki te whakahaere i te mate HSV.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 1 (HSV-1) is a member of the Alphaherpesviridae subfamily. Its structure is composed of linear dsDNA, an icosahedral capsid that is 100 to 110 nm in diameter, with a spikey envelope. In general, the pathogenesis of HSV-1 infection follows a cycle of primary infection of epithelial cells, latency primarily in neurons, and reactivation. HSV-1 is responsible for establishing primary and recurrent vesicular eruptions, primarily in the orolabial and genital mucosa. HSV-1 infection has a wide variety of presentations, including orolabial herpes, herpetic sycosis (HSV folliculitis), herpes gladiatorum, herpetic whitlow, ocular HSV infection, herpes encephalitis, Kaposi varicelliform eruption (eczema herpeticum), and severe or chronic HSV infection. Antiviral therapy limits the course of HSV infection.
Herpes simplex virus type 2 (HSV-2) he mate whanui, e pa ana ki te 22 % o nga pakeke 12 tau ki runga ake, e 45 miriona nga pakeke i te United States. Ahakoa ko te HSV-1 te nuinga o te wā ka pa mai te māmae o te waha, ka taea hoki te ara arahi ki ngā rewharewha. Heoi, ka pa ana ngā turoro ki te mate herpes rewharewha (genital herpes), ko te nuinga o te wā ko HSV-2 te tino awangawanga. Ko ngā tohu o te pakarutanga o te HSV-2 he maha ngā wā karekau, pērā i te patito me te irirangi o te herpes rewharewha (genital herpes), ka taea te whakaroa i te tātaritanga me te maimoatanga. Ko tēnei whakaroa ka hua pea te tuku atu ki ngā tangata kāore i pangia.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus type 2 (HSV-2) continues to be a common infection, affecting approximately 22% of adults ages 12 and older, representing 45 million adults in the United States alone. While HSV-1 often affects the perioral region and can be known to cause genital lesions, HSV-2 is more commonly the consideration when patients present with genital lesions. Despite this, most outbreaks of the infection will present with nonspecific symptoms such as genital itching, irritation, and excoriations, which may cause diagnosis and treatment to be delayed. As a result, further exposure to uninfected individuals may occur.
Herpes simplex virus (HSV) te nuinga o te wa ka pa mai nga mate penei i te herpes me te tuwhenua makariri i roto i nga taiohi me nga pakeke. Ina pangia e te HSV tetahi kohungahunga i roto i nga wiki 4‑6 tuatahi o te oranga, ka puta he mate kino me nga hua kino. He mea tino nui te whakatau tere i te mate HSV neonatal ki te aukati i te kino o te mate, me te aukati i nga take neurological (tae noa ki te mate).
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex virus (HSV), a member of the Herpesviridae family, is a well-known cause of infections including genital herpes and herpes labialis in the adolescent and adult population. Transmission of HSV infection to an infant during the first 4-6 weeks of life can lead to devastating disease with the potential for poor outcomes. Early diagnosis is imperative when evaluating neonatal HSV infection in order to prevent further disease progression, neurological complications, and even death.
Herpes simplex he tino noa te mate, ka taea te tuku mai i nga wahine hapu ki a ratou kohungahunga. Ka taea e tenei virusi herpes (herpes virus) te mate kino ki te hauora, te mate ranei o nga tamariki hou. Ahakoa he onge i te wa e hapu ana, he maha nga wa ka puta i te wa e whanau ana. Ka nui ake te mate mena ka pangia te whaea i nga wahanga o muri o te haputanga. Heoi, ka taea te whakaiti i tenei raru ma te whakamahi i nga rāurau antiviral (antiviral drugs), te whiriwhiri ranei mo te waahanga‑C i etahi ahuatanga.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Infection with herpes simplex is one of the most common sexually transmitted infections. Because the infection is common in women of reproductive age it can be contracted and transmitted to the fetus during pregnancy and the newborn. Herpes simplex virus is an important cause of neonatal infection, which can lead to death or long-term disabilities. Rarely in the uterus, it occurs frequently during the transmission delivery. The greatest risk of transmission to the fetus and the newborn occurs in case of an initial maternal infection contracted in the second half of pregnancy. The risk of transmission of maternal-fetal-neonatal herpes simplex can be decreased by performing a treatment with antiviral drugs or resorting to a caesarean section in some specific cases.
Herpes simplex virus (HSV) momo 1 me te 2 ka pangia e te tini o nga tangata puta noa i te ao. I te nuinga o te wa, ka noho humarie te huaketo i roto i nga pūtau nerve i muri i te pangia o te kiri, engari ka taea te whakaara ano i muri mai, ka puta nga mate makariri. I etahi wa, ka pa atu ki nga raru nui penei i te mate kanohi, te mumura o te roro, nga ahuatanga kino ranei i roto i nga whanau hou me nga taangata ngoikore te punaha mate. Ahakoa ka awhina nga rongoa o naianei ki te whakahaere i nga mate, ko te tupono o te aukati i nga raau taero me nga paanga taha ka noho tonu hei awangawanga. Kei te hiahia matou ki nga raau taero hou kia pai ake te aro ki te huaketo.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
Infection with herpes simplex virus (HSV) types 1 and 2 is ubiquitous in the human population. Most commonly, virus replication is limited to the epithelia and establishes latency in enervating sensory neurons, reactivating periodically to produce localized recurrent lesions. However, these viruses can also cause severe disease such as recurrent keratitis leading potentially to blindness, as well as encephalitis, and systemic disease in neonates and immunocompromised patients. Although antiviral therapy has allowed continual and substantial improvement in the management of both primary and recurrent infections, resistance to currently available drugs and long-term toxicity pose a current and future threat that should be addressed through the development of new antiviral compounds directed against new targets.
A ape i te pa atu ki te tinana, penei i te kihi i te tamaiti, i te mea kei te mau te opupu, na te mea ka pa atu te mate ki etahi atu tangata. Me okioki koe me te kore e inu waipiro.
aciclovir cream (Acyclovir)